Potential impact of long-term nucleoside therapy on the mortality and morbidity of active chronic hepatitis B #
Open Access
- 27 August 2009
- journal article
- viral hepatitis
- Published by Wolters Kluwer Health in Hepatology
- Vol. 50 (3), 743-751
- https://doi.org/10.1002/hep.23061
Abstract
The potential impact of long-term antiviral therapy on the burden of chronic hepatitis B has hardly been documented. The aim of this study was to estimate the effects of prolonged antiviral therapy and antiviral resistance on the mortality and morbidity of active chronic hepatitis B patients. A population cohort of chronic hepatitis B patients in the Netherlands was constructed and stratified according to 10-year age groups, prevalence of hepatitis B surface antigen, hepatitis B virus DNA level, alanine aminotransferase level, hepatitis B e antigen status, and presence of cirrhosis. A Markov model was created to mathematically simulate the cohort's progression through a finite series of health states. The analysis was performed on the basis of four scenarios: natural history, long-term therapy with a high-resistance profile drug without or with salvage, and therapy with a low-resistance profile drug. It has been estimated that there were 64,000 people (0.4%) suffering from chronic hepatitis B infection in the Netherlands in 2005, with 6521 (10%) of them having high viremia and elevated alanine aminotransferase levels. Within a 20-year period, 1725 (26%) of the 6521 patients in the active chronic hepatitis B cohort will die because of liver-related causes. Of the 5685 without cirrhosis at entry, 1671 (29%) will develop cirrhosis. Of those 836 with cirrhosis at entry, 619 (74%) will die within a 20-year period. If this active chronic hepatitis B cohort is fully detected and treated, mortality related to liver disease can be reduced by 80% if a low-resistance profile drug is chosen from the start. The effect is due to both the reduction in complications of cirrhosis and the prevention of the development of cirrhosis. Conclusion: Long-term antiviral therapy with a strategy that minimizes or controls resistance will have a major preventive effect on liver-related mortality and morbidity. (Hepatology 2009.)Keywords
This publication has 33 references indexed in Scilit:
- High impact of migration on the prevalence of chronic hepatitis B in the NetherlandsEuropean Journal of Gastroenterology & Hepatology, 2008
- The global impact of vaccination against hepatitis B: A historical overviewVaccine, 2008
- Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen–positive chronic hepatitis BHepatology, 2008
- Accuracy of a referral guideline for patients with chronic hepatitis B in primary care to select patients eligible for evaluation by a specialistGut, 2007
- Chronic hepatitis BHepatology, 2007
- The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwideJournal of Hepatology, 2006
- Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trialThe Lancet, 2005
- Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver DiseaseNew England Journal of Medicine, 2004
- Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Negative Chronic Hepatitis BNew England Journal of Medicine, 2003
- Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis BHepatology, 2000